Exhibit 99.1

Aldeyra Therapeutics Announces Year End 2017 Financial Results

LEXINGTON, Mass., Mar. 29, 2018 /PRNewswire/ — Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced financial results for the year ended December 31, 2017.

“2017 was a productive year for Aldeyra, highlighted by favorable clinical results in dry eye disease and allergic conjunctivitis, initiation of a Phase 3 clinical trial in noninfectious anterior uveitis, and receipt of orphan drug designation for reproxalap in Sjögren-Larsson Syndrome,” commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “Our progress has continued in 2018, having recently enrolled the first patient into our Phase 2b dry eye disease clinical trial, and with the signing of our development partnership with Janssen Research & Development, a Johnson & Johnson company. We look forward to sharing important milestones across multiple pipeline programs in 2018.”

Key 2017 Highlights and Upcoming Events

 

    Reported favorable Phase 2a clinical data in dry eye disease and initiated enrollment of Phase 2b clinical trial. In September 2017, Aldeyra reported positive results from a randomized, dose-ranging, parallel-group, double-masked Phase 2a clinical trial of topical ocular reproxalap in dry eye disease patients. Reproxalap demonstrated statistically and clinically significant improvement across multiple sign and symptom scores. Improvements in dry eye disease signs and symptoms were evident within one week of therapy and effect sizes increased over the duration of therapy, supportive of rapid drug activity relative to standard of care. Aldeyra enrolled its first patient into a Phase 2b clinical trial of reproxalap in dry eye disease in January 2018, and expects to report results in the second half of 2018.

 

    Planned initiation of Phase 3 clinical trial in allergic conjunctivitis. Based on an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) following favorable results from Aldeyra’s Phase 2b clinical trial in allergic conjunctivitis, Aldeyra plans to begin a Phase 3 allergic conjunctivitis clinical trial of topical ocular reproxalap in the first half of 2018. Results of the Phase 3 clinical trial are expected in the second half of 2018, or early 2019.

 

   

Presented Phase 2 clinical results in noninfectious anterior uveitis (NAU) at ophthalmic medical conferences and initiated Phase 3 clinical trial. In May 2017, Dr. John Sheppard, an internationally recognized expert in anterior ocular inflammation, presented the results of Aldeyra’s Phase 2 clinical trial of topical ocular reproxalap in NAU as an Emerging Treatments paper at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting. Data from the trial demonstrated activity comparable to Pred Forte®, a standard-of-care topical ocular corticosteroid, in reducing anterior chamber inflammatory cell count in patients with active NAU, without increasing intraocular pressure, a major side effect of corticosteroids. In November 2017, Dr. Sheppard presented additional analyses of Aldeyra’s Phase 2 clinical trial at the American Uveitis Society held at the American Academy of Ophthalmology 2017 Annual Meeting. The results of the analyses demonstrated formal statistical non-inferiority of 0.5% reproxalap ophthalmic solution to Pred Forte® in reducing


The following information was filed by Aldeyra Therapeutics, Inc. (ALDX) on Thursday, March 29, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Aldeyra Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aldeyra Therapeutics, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account